MRD / monitoring · curated MDI catalog

MRD and cancer monitoring molecular tests

MRD and monitoring tests look for molecular evidence of disease over time after diagnosis or treatment. Results depend on assay design, timing, threshold, cancer context and the version that was studied.

18 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • CanCatch Custom — Tumor-informed personalized ctDNA MRD approach using WES baseline profiling and patient-specific mutation tracking.
  • CancerVista — ctDNA liquid-biopsy in-house IVD for MRD detection, recurrence surveillance and therapy monitoring across solid tumors.
  • clonoSEQ — NGS-based clonotype assay for measurable/minimal residual disease assessment in lymphoid malignancies, with disease- and specimen-specific FDA-cleared contexts and additional LDT uses.
  • Foresight CLARITY — Ultra-sensitive ctDNA molecular residual disease assay using PhasED-Seq phased-variant detection, with strong current use in B-cell lymphoma clinical programs.
  • FoundationOne MRD — Tissue-informed ctDNA MRD assay for stage II-III breast cancer using tumor WGS and multiplex dPCR.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Haystack MRD — Tumor-informed ctDNA molecular residual disease assay for solid tumors using WES-derived personalized panels tracking up to 50 variants.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • Labcorp Plasma Detect Genome MRD — Tumor-informed whole-genome sequencing ctDNA MRD test currently offered for stage III colon cancer baseline and monitoring.
  • LymphoVista — ctDNA sequencing in-house IVD for lymphoma genotyping, MRD assessment and longitudinal monitoring.
  • NavDx — Blood-based TTMV-HPV DNA laboratory-developed test used in HPV-driven cancer management and post-treatment recurrence surveillance.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • Northstar Response — Tissue-free methylated-ctDNA liquid biopsy for quantitative treatment-response monitoring across advanced solid tumors.
  • Oncodetect MRD — Tumor-informed ctDNA molecular residual disease test used across solid tumors; current commercial configuration tracks up to 200 tumor-specific variants.
  • Precise MRD — Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
  • RaDaR ST — Personalized tumor-informed ctDNA MRD assay for solid tumors; current ST generation uses WES tumor profiling and tracks up to 48 patient-specific mutations.
  • Signatera — Personalized tumor-informed circulating tumor DNA molecular residual disease test family. Includes the FDA-authorized Signatera CDx MIBC companion-diagnostic configuration and broader laboratory-developed clinical uses that remain separately scoped.
  • Tempus xM — Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance